Representative Jefferson Shreve (R-Indiana) recently bought shares of Stryker Co. NYSE: SYK. In a filing disclosed on May 08th, the Representative disclosed that they had bought between $15,001 and $50,000 in Stryker stock on April 17th.
Representative Jefferson Shreve also recently made the following trade(s):
- Purchased $50,001 - $100,000 in shares of Chipotle Mexican Grill NYSE: CMG on 4/17/2025.
- Purchased $50,001 - $100,000 in shares of Applied Materials NASDAQ: AMAT on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Caterpillar NYSE: CAT on 4/17/2025.
- Sold $15,001 - $50,000 in shares of Lululemon Athletica NASDAQ: LULU on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Western Digital NASDAQ: WDC on 4/17/2025.
- Sold $15,001 - $50,000 in shares of Zoetis NYSE: ZTS on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of NextEra Energy NYSE: NEE on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of CSX NASDAQ: CSX on 4/17/2025.
- Purchased $15,001 - $50,000 in shares of Ross Stores NASDAQ: ROST on 4/17/2025.
- Sold $15,001 - $50,000 in shares of Meta Platforms NASDAQ: META on 4/17/2025.
Stryker Stock Performance
Shares of NYSE:SYK traded up $7.05 during trading on Monday, hitting $387.97. 1,359,329 shares of the stock traded hands, compared to its average volume of 1,356,022. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The company has a fifty day moving average price of $365.31 and a two-hundred day moving average price of $374.73. Stryker Co. has a 52-week low of $314.93 and a 52-week high of $406.19. The company has a market cap of $148.08 billion, a price-to-earnings ratio of 50.00, a P/E/G ratio of 2.93 and a beta of 0.93.
Stryker (NYSE:SYK - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping analysts' consensus estimates of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion during the quarter, compared to the consensus estimate of $5.68 billion. During the same quarter in the prior year, the firm posted $2.50 earnings per share. The company's revenue was up 11.9% compared to the same quarter last year. As a group, equities analysts predict that Stryker Co. will post 13.47 EPS for the current year.
Stryker Dividend Announcement
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be paid a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.87%. Stryker's payout ratio is 45.41%.
Insider Activity at Stryker
In other news, Director Allan C. Golston sold 2,458 shares of the stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the sale, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This trade represents a 14.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 200,000 shares of the business's stock in a transaction on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the transaction, the director now directly owns 3,417,326 shares of the company's stock, valued at $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company's stock.
Analyst Upgrades and Downgrades
SYK has been the topic of a number of research analyst reports. JMP Securities reissued a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. Sanford C. Bernstein set a $450.00 price target on Stryker in a research report on Monday, May 5th. Evercore ISI lowered their target price on shares of Stryker from $400.00 to $390.00 and set an "outperform" rating on the stock in a research note on Friday, May 2nd. StockNews.com lowered shares of Stryker from a "buy" rating to a "hold" rating in a report on Thursday, March 6th. Finally, Argus set a $450.00 price target on shares of Stryker in a research note on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat.com, Stryker presently has a consensus rating of "Moderate Buy" and an average target price of $427.05.
Read Our Latest Research Report on SYK
Institutional Trading of Stryker
A number of hedge funds and other institutional investors have recently modified their holdings of SYK. Principal Financial Group Inc. raised its holdings in shares of Stryker by 6.2% in the 3rd quarter. Principal Financial Group Inc. now owns 398,422 shares of the medical technology company's stock valued at $143,934,000 after buying an additional 23,329 shares during the period. Rempart Asset Management Inc. increased its stake in Stryker by 5.0% during the fourth quarter. Rempart Asset Management Inc. now owns 49,496 shares of the medical technology company's stock worth $17,821,000 after purchasing an additional 2,351 shares during the period. ST Germain D J Co. Inc. lifted its position in shares of Stryker by 14.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 2,362 shares of the medical technology company's stock worth $850,000 after purchasing an additional 300 shares in the last quarter. Sugarloaf Wealth Management LLC boosted its stake in shares of Stryker by 11.2% in the fourth quarter. Sugarloaf Wealth Management LLC now owns 496 shares of the medical technology company's stock valued at $179,000 after purchasing an additional 50 shares during the period. Finally, Tilia Fiduciary Partners Inc. grew its holdings in shares of Stryker by 3.6% in the fourth quarter. Tilia Fiduciary Partners Inc. now owns 7,075 shares of the medical technology company's stock valued at $2,548,000 after purchasing an additional 243 shares in the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.
About Representative Shreve
Jefferson Shreve (Republican Party) is a member of the U.S. House, representing Indiana's 6th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.
Shreve (Republican Party) is running for re-election to the U.S. House to represent Indiana's 6th Congressional District. He declared candidacy for the 2026 election.
Email editor@ballotpedia.org to notify us of updates to this biography.
Jefferson Shreve earned a bachelor's degree from Indiana University in 1989, a graduate degree from the University of London in 1998, and a graduate degree from Purdue University in 2003. Shreve's career experience includes working as a real estate executive.
Shreve was elected 7th District Vice Chairman of the Indiana Republican State Committee on January 17, 2018, and was re-elected on March 6, 2021. In 2020, he was selected as a district-level delegate to the 2020 Republican National Convention.
About Stryker
(
Get Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Further Reading
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
